Completed NA INTERVENTIONAL 2-arm NCT04732793

To Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in Europe

A Prospective, Active Controlled, Randomised, Parallel Group, Double Blind, Multicentre Study to Assess the Safety and Effectiveness of Hyruan ONE Versus a Comparator for the Treatment of Knee Osteoarthritis in Europe

Sponsor: LG Chem

Conditions Osteoarthritis (OA) of the Knee

Interventions Durolane® Hyruan ONE®

Updated 5 times since 2021 Last updated: Mar 15, 2022 Started: Feb 3, 2021 Primary completion: Jun 11, 2021 Completion: Dec 7, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04732793, this NA trial focuses on Osteoarthritis (OA) of the Knee and remains completed. Sponsored by LG Chem, it has been updated 5 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Apr 2022 — Jul 2024 [monthly]

Completed NA

Status: Active Not Recruiting → Completed
Dec 2021 — Apr 2022 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting
Mar 2021 — Dec 2021 [monthly]

Recruiting NA

First recorded

Feb 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LG Chem

Data source: LG Chem

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Świdnik, Poland